查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552919

医院感染控制市场规模、份额、趋势分析报告：按类型、最终用途、地区、细分市场预测，2024-2030 年

Hospital Acquired Infection Control Market Size, Share & Trends Analysis Report By Type (Equipment, Services, Consumables), By End Use (Hospitals & ICUs), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

医院感染控制市场的成长和趋势

Grand View Research, Inc.的最新报告显示，到2030年，全球医院感染控制市场规模预计将达到90.3亿美元。

预计 2024 年至 2030 年，该市场将以 5.2% 的复合年增长率扩张。推动市场成长的关键因素包括医院获得性感染 (HAI) 发病率上升、政府支持措施和 COVID-19 大流行。 COVID-19 大流行提高了人们对 HAI 的认识和担忧，并已成为市场的主要催化剂。阻止 COVID-19 传播的需求也推动了对感染控制设备和用品的需求。

各国政府和监管机构制定了多项政策和准则，以防止交叉污染并保护公众健康。除了洗手和使用个人防护工具等标准预防措施外，还实施了分流策略、设备提供和适当分配等感染控制标准，以预防医疗机构中的院内感染。特别是，疫情导致个人防护装备、口罩、消毒剂等消耗品需求激增。

美国卫生与公众服务部 CDC 开发了一个关于基本感染预防和控制、抗生素抗药性、设备相关感染、手术相关感染以及疾病/感染的广泛指南库，以帮助控制 HAI。大流行结束后，CDC 在其数位图书馆中添加了 COVID-19 感染控制指南。

市场参与企业不断增加的倡议也促进了市场的成长。这些措施包括策略伙伴关係、併购和产品开发。例如，2021年2月，Getinge扩大了与XPO Logistics的合作关係，后者将为该公司的感染控制业务部门提供从荷兰到欧洲、中东和非洲地区的仓储和运输服务。 2020 年 12 月，Xenex 推出了 LightStrike 6，作为其病原体清除机器人专利系列的一部分。该机器人还可以产生高强度、广谱紫外线，在两分钟内惰性COVID-19 病毒。

医院感染控制市场报告亮点

  • 消耗品领域占市场主导地位，2023 年收益占有率最大，为 46.9%。这是由于医院和门诊医疗中心消耗品的高使用率。 COVID-19 大流行进一步增加了该细分市场的份额，因为它增加了对一次性、安全且有效的解决方案来遏制病毒传播的需求。这包括 N95 口罩、个人防护装备和手套等产品。
  • 由于医院和加护病房(ICU) 部门的医疗保健相关感染 (HCAI) 发生率较高，因此 2023 年该部门的收入份额最大，为 45.9%。 CDC 估计，每 31 名医院患者中就有 1 名每天至少患有一次医院感染。
  • 在亚太地区，由于政府加强推广抗 HAI 产品，预计未来几年市场将出现良好成长。
  • 市场参与企业的策略性倡议包括併购、联盟、地理扩张和新产品开拓。例如，2020年11月，Getinge收购了去污产品製造商Quadralene。该公司已整合到 Getinge 的感染控制产品组合中，扩大了其在手术工作流程业务领域的产品范围。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章 医院感染控制市场的变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 医院感染控制市场分析工具
    • 波特的分析
    • PESTEL分析

第四章医院感染控制市场：按类型估计和趋势分析

  • 细分仪表板
  • 医院感染控制市场：类型变化分析，2023 年和 2030 年
  • 装置
  • 服务
  • 消耗品

第五章医院感染控制市场：依最终用途分类的估计与趋势分析

  • 细分仪表板
  • 医院感染控制市场：2023 年和 2030 年最终用途变化分析
  • 医院及加护病房(ICU)
  • 门诊手术/诊断中心
  • 其他的

第六章 医院感染控制市场：区域估计与趋势分析

  • 2023 年及 2030 年医院感染控制市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • 3M Company
    • Belimed AG
    • O&M Halyards
    • Getinge
    • ASP
    • Sterigenics US, LLC-A Sotera Health Company
    • MMM Group
    • Cantel Medical Corp.（Medivators Inc.）
    • Midmark Corporation
    • STERIS
    • W&H
简介目录
Product Code: GVR-4-68039-383-5

Hospital Acquired Infection Control Market Growth & Trends:

The global hospital acquired infection control market size is anticipated to reach USD 9.03 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 5.2% from 2024 to 2030. The key factors driving the market growth include the rising incidence of Hospital Acquired Infections (HAIs), supportive government initiatives, and the COVID-19 pandemic. The COVID-19 pandemic has emerged as a major catalyst for the market as it led to increased awareness and concern over HAIs. The demand for infection control equipment and consumables also stemmed from the need to stop the spread of COVID-19.

Governments and regulatory bodies prescribed several policies and guidelines to prevent cross-contamination and safeguard public health. To prevent nosocomial infections in healthcare facilities, infection control standards were implemented such as triage strategy and provision and proper distribution of equipment, in addition to standard precautions such as hand washing and use of personal protective equipment. In particular, the pandemic resulted in a surge in demand for consumables such as PPE, masks, and disinfectants.

The CDC, of the U.S. Department of Health and Human Services, provides an extensive library of guidelines on basic infection prevention and control, antibiotic resistance, device-associated infections, procedure-associated infections, and disease / organism-specific to promote the control of HAIs. In the wake of the pandemic, the CDC added COVID-19 infection control guidelines to its digital library.

Growing initiatives by market players also contribute to the growth of the market. These initiatives include strategic partnerships, mergers and acquisitions, and product development. In February 2021, for instance, Getinge expanded its partnership with XPO Logistics under which the latter will provide warehousing and transport services from the Netherlands to the EMEA region for the company's infection control business unit. In December 2020, Xenex launched LightStrike 6 as part of its patented lineup of pathogen-eliminating robots. The robots produce high-intensity broad-spectrum UV light and can also deactivate the COVID-19 virus in 2 minutes.

Hospital Acquired Infection Control Market Report Highlights:

  • The consumables segment dominated the market and accounted for the largest revenue share of 46.9% in 2023. This was owing to the high usage of consumables in hospitals and ambulatory care centers. The COVID-19 pandemic further contributed to the segment share due to the increased need for disposable, safe, and effective solutions to curb the spread of the virus. These included products such as N95 masks, PPE, and gloves
  • The hospitals and Intensive Care Units (ICUs) segment held the largest revenue share of 45.9% in 2023 due to the high prevalence of healthcare-associated infections (HCAIs) in these facilities. According to CDC estimates, about 1 out of 31 hospital patients suffer from at least one HAI on any given day
  • In Asia Pacific, the market is anticipated to witness lucrative growth in coming years owing to increasing supportive government initiatives to promote HAIs control products in the region
  • Strategic initiatives by market players are mergers and acquisitions, collaboration, geographic expansions, and new product development. For example, in November 2020, Getinge acquired a manufacturer of decontamination products-Quadralene. The company was merged into Getinge's Infection Control portfolio to expand its offerings in the business area of Surgical Workflows

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hospital Acquired Infection Control Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Hospital Acquired Infection Control Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1 Bargaining power of the suppliers
      • 3.4.1.2 Bargaining power of the buyers
      • 3.4.1.3 Threats of substitution
      • 3.4.1.4 Threats from new entrants
      • 3.4.1.5 Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1 Political landscape
      • 3.4.2.2 Economic and Social landscape
      • 3.4.2.3 Technological landscape
      • 3.4.2.4 Environmental landscape
      • 3.4.2.5 Legal landscape

Chapter 4. Hospital Acquired Infection Control Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hospital Acquired Infection Control Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Equipment
    • 4.3.1. Equipment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Sterilization Equipment
      • 4.3.2.1 Sterilization Equipment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.2 Heat Sterilization Equipment
        • 4.3.2.2.1. Heat Sterilization Equipment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.2.2. Moist Heat Sterilization
          • 4.3.2.2.2.1. Moist Heat Sterilization Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.3. Dry Heat Sterilization
        • 4.3.2.3.1. Dry Heat Sterilization Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3 Low Temperature Sterilization
      • 4.3.3.1. Low Temperature Sterilization Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4 Radiation Sterilization
      • 4.3.4.1. Radiation Sterilization Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5 Others
      • 4.3.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.6. Disinfection Equipment
      • 4.3.6.1 Disinfection Equipment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.6.2 Washer Disinfector
        • 4.3.6.2.1 Washer Disinfector Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.7 Flusher Disinfector
      • 4.3.7.1. Flusher Disinfector Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.7.2 Endoscopic Reprocessor Systems
        • 4.3.7.2.1 Endoscopic Reprocessor Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Services
    • 4.4.1. Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Consumables
    • 4.5.1. Consumables Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Disinfectants
      • 4.5.2.1 Disinfectants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Sterilization Consumables
      • 4.5.3.1 Sterilization Consumables Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hospital Acquired Infection Control Market: End Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Hospital Acquired Infection Control Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Hospitals and Intensive Care Units (ICUs)
    • 5.3.1. Hospitals and Intensive Care Units (ICUs) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Ambulatory Surgical and Diagnostic Centers
    • 5.4.1. Ambulatory Surgical and Diagnostic Centers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hospital Acquired Infection Control Market: Regional Estimates & Trend Analysis

  • 6.1. Hospital Acquired Infection Control Market Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Hospital Acquired Infection Control Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1 U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1 Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1 Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Hospital Acquired Infection Control Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1 UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1 Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1 France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1 Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1 Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1 Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1 Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1 Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Hospital Acquired Infection Control Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1 Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1 China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1 India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1 Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. South Korea
      • 6.4.6.1 South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1 Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Hospital Acquired Infection Control Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1 Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1 Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East & Africa (MEA)
    • 6.6.1. MEA Hospital Acquired Infection Control Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1 South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1 Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1 UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1 Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. 3M Company
      • 7.4.1.1 Participant's Overview
      • 7.4.1.2 Financial Performance
      • 7.4.1.3 Product Benchmarking
      • 7.4.1.4 Recent Developments/Strategic Initiatives
    • 7.4.2. Belimed AG
      • 7.4.2.1 Participant's Overview
      • 7.4.2.2 Financial Performance
      • 7.4.2.3 Product Benchmarking
      • 7.4.2.4 Recent Developments/Strategic Initiatives
    • 7.4.3. O&M Halyards
      • 7.4.3.1 Participant's Overview
      • 7.4.3.2 Financial Performance
      • 7.4.3.3 Product Benchmarking
      • 7.4.3.4 Recent Developments/Strategic Initiatives
    • 7.4.4. Getinge
      • 7.4.4.1 Participant's Overview
      • 7.4.4.2 Financial Performance
      • 7.4.4.3 Product Benchmarking
      • 7.4.4.4 Recent Developments/Strategic Initiatives
    • 7.4.5. ASP
      • 7.4.5.1 Participant's Overview
      • 7.4.5.2 Financial Performance
      • 7.4.5.3 Product Benchmarking
      • 7.4.5.4 Recent Developments/Strategic Initiatives
    • 7.4.6. Sterigenics U.S., LLC - A Sotera Health Company
      • 7.4.6.1 Participant's Overview
      • 7.4.6.2 Financial Performance
      • 7.4.6.3 Product Benchmarking
      • 7.4.6.4 Recent Developments/Strategic Initiatives
    • 7.4.7. MMM Group
      • 7.4.7.1 Participant's Overview
      • 7.4.7.2 Financial Performance
      • 7.4.7.3 Product Benchmarking
      • 7.4.7.4 Recent Developments/Strategic Initiatives
    • 7.4.8. Cantel Medical Corp. (Medivators Inc.)
      • 7.4.8.1 Participant's Overview
      • 7.4.8.2 Financial Performance
      • 7.4.8.3 Product Benchmarking
      • 7.4.8.4 Recent Developments/Strategic Initiatives
    • 7.4.9. Midmark Corporation
      • 7.4.9.1 Participant's Overview
      • 7.4.9.2 Financial Performance
      • 7.4.9.3 Product Benchmarking
      • 7.4.9.4 Recent Developments/Strategic Initiatives
    • 7.4.10. STERIS
      • 7.4.10.1 Participant's Overview
      • 7.4.10.2 Financial Performance
      • 7.4.10.3 Product Benchmarking
      • 7.4.10.4 Recent Developments/Strategic Initiatives
    • 7.4.11. W&H
      • 7.4.11.1 Participant's Overview
      • 7.4.11.2 Financial Performance
      • 7.4.11.3 Product Benchmarking
      • 7.4.11.4 Recent Developments/Strategic Initiatives